Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate-2 or high-risk myelofibrosis.

"Financial disclosures Animesh Pardanani declares no conflicts. Ayalew Tefferi declares no conflicts. Tamás Masszi reports Advisory Committee participation for Abbvie, BMS, Janssen‐Cilag, Novartis, Pfizer, and Takeda. Elena Mishchenko declares no conflicts. Mark Drummond : Speakers’ Bureau: Novartis, BMS, Astellas, Jazz; Advisory Committee participation: Novartis, BMS, Pfizer; Research Funding: Novartis, BMS/Celgene. Eric Jourdan reports consulting fees and Advisory Committee participation for Novartis, BMS/Celgene, Astallas, and Abbvie. Alessandro Vannucchi holds positions on advisory committees for Novartis, Celgene (a Bristol‐Myers Squibb Company), Abbvie, Blueprint, and Incyte; and participates in speakers’ bureau for Novartis, Celgene (a Bristol‐Myers Squibb Company), and Abbvie. Mindaugas Jurgutis declares no conflicts. Vincent Ribrag reports ad board participation for Gilead, Infinity, MSD, BMS, Nanostring, Incyte, Roche, AstraZeneca; Research Funding from Astex, Argen‐X, and GSK. Alessandro Rambaldi reports personal fees from Celgene BMS, Sanofi, Novartis, Italfarmaco, Amgen, Pfizer, kite Gilead, Astellas, Jazz. Liang Piu Koh declares no conflicts. Shelonitda Rose and Jun Zhang report employment and equity ownership in BMS. Claire Harrison reports consultancy for Celgene, Novartis, CTI, Roche, Promedior, Galacteo, Sierra Oncology, Constellation, Janssen, and Geron; Honoraria from Celgene, Novartis, Roche, AOP Pharma; and Speakers’ Bureau participation for Celgene, Novartis, CTI, and Janssen."

"We thank the patients, families, co‐investigators, and all study personnel who participated in this trial. The original study was supported by Sanofi S.A.; this re‐analysis was funded by Celgene, a Bristol‐Myers Squibb company. The authors received editorial assistance on an early draft from Brian Kaiser and Sheila Truten (Medical Communication Company, Inc.), sponsored by Bristol‐Myers Squibb. The authors are fully responsible for all content and editorial decisions, and all approved submission of the final manuscript. Financial disclosures Animesh Pardanani declares no conflicts. Ayalew Tefferi declares no conflicts. Tamás Masszi reports Advisory Committee participation for Abbvie, BMS, Janssen‐Cilag, Novartis, Pfizer, and Takeda. Elena Mishchenko declares no conflicts. Mark Drummond : Speakers’ Bureau: Novartis, BMS, Astellas, Jazz; Advisory Committee participation: Novartis, BMS, Pfizer; Research Funding: Novartis, BMS/Celgene. Eric Jourdan reports consulting fees and Advisory Committee participation for Novartis, BMS/Celgene, Astallas, and Abbvie. Alessandro Vannucchi holds positions on advisory committees for Novartis, Celgene (a Bristol‐Myers Squibb Company), Abbvie, Blueprint, and Incyte; and participates in speakers’ bureau for Novartis, Celgene (a Bristol‐Myers Squibb Company), and Abbvie. Mindaugas Jurgutis declares no conflicts. Vincent Ribrag reports ad board participation for Gilead, Infinity, MSD, BMS, Nanostring, Incyte, Roche, AstraZeneca; Research Funding from Astex, Argen‐X, and GSK. Alessandro Rambaldi reports personal fees from Celgene BMS, Sanofi, Novartis, Italfarmaco, Amgen, Pfizer, kite Gilead, Astellas, Jazz. Liang Piu Koh declares no conflicts. Shelonitda Rose and Jun Zhang report employment and equity ownership in BMS. Claire Harrison reports consultancy for Celgene, Novartis, CTI, Roche, Promedior, Galacteo, Sierra Oncology, Constellation, Janssen, and Geron; Honoraria from Celgene, Novartis, Roche, AOP Pharma; and Speakers’ Bureau participation for Celgene, Novartis, CTI, and Janssen."